1psk: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
New page: left|200px<br /> <applet load="1psk" size="450" color="white" frame="true" align="right" spinBox="true" caption="1psk, resolution 2.8Å" /> '''THE CRYSTAL STRUCTUR...
 
No edit summary
Line 1: Line 1:
[[Image:1psk.gif|left|200px]]<br />
[[Image:1psk.gif|left|200px]]<br /><applet load="1psk" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1psk" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1psk, resolution 2.8&Aring;" />
caption="1psk, resolution 2.8&Aring;" />
'''THE CRYSTAL STRUCTURE OF AN FAB FRAGMENT THAT BINDS TO THE MELANOMA-ASSOCIATED GD2 GANGLIOSIDE'''<br />
'''THE CRYSTAL STRUCTURE OF AN FAB FRAGMENT THAT BINDS TO THE MELANOMA-ASSOCIATED GD2 GANGLIOSIDE'''<br />


==Overview==
==Overview==
The GD2 ganglioside is a cell-surface component that appears on the, surface of metastatic melanoma cells and is a marker for the progression, of the disease. The ME36.1 monoclonal antibody binds to the GD2, ganglioside and has shown potential as a therapeutic antibody. ME36.1 is a, possible alternative therapy to radiation, which is often ineffective in, late-stage melanoma. The crystal structure of the Fab fragment of ME36.1, has been determined using molecular replacement and refined to an R factor, of 20.4% at 2.8 A resolution. The model has good geometry with, root-mean-square deviations of 0.008 A from ideal bond lengths and 1.7, degrees from ideal bond angles. The crystal structure of the ME36.1 Fab, shows that its complementarity determining region forms a groove-shaped, binding site rather than the pocket-type observed in other sugar binding, Fabs. Molecular modeling has placed a four-residue sugar, representative, of GD2, in the antigen binding site. The GD2 sugar moiety is stabilized by, a network of hydrogen bonds that define the specificity of ME36.1 toward, its antigen.
The GD2 ganglioside is a cell-surface component that appears on the surface of metastatic melanoma cells and is a marker for the progression of the disease. The ME36.1 monoclonal antibody binds to the GD2 ganglioside and has shown potential as a therapeutic antibody. ME36.1 is a possible alternative therapy to radiation, which is often ineffective in late-stage melanoma. The crystal structure of the Fab fragment of ME36.1 has been determined using molecular replacement and refined to an R factor of 20.4% at 2.8 A resolution. The model has good geometry with root-mean-square deviations of 0.008 A from ideal bond lengths and 1.7 degrees from ideal bond angles. The crystal structure of the ME36.1 Fab shows that its complementarity determining region forms a groove-shaped binding site rather than the pocket-type observed in other sugar binding Fabs. Molecular modeling has placed a four-residue sugar, representative of GD2, in the antigen binding site. The GD2 sugar moiety is stabilized by a network of hydrogen bonds that define the specificity of ME36.1 toward its antigen.


==About this Structure==
==About this Structure==
1PSK is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1PSK OCA].  
1PSK is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1PSK OCA].  


==Reference==
==Reference==
Line 14: Line 13:
[[Category: Mus musculus]]
[[Category: Mus musculus]]
[[Category: Protein complex]]
[[Category: Protein complex]]
[[Category: Burnett, R.M.]]
[[Category: Burnett, R M.]]
[[Category: Murali, R.]]
[[Category: Murali, R.]]
[[Category: Pichla, S.L.]]
[[Category: Pichla, S L.]]
[[Category: carbohydrate]]
[[Category: carbohydrate]]
[[Category: fab]]
[[Category: fab]]
Line 23: Line 22:
[[Category: melanoma]]
[[Category: melanoma]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Sun Nov 18 09:39:47 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:32:06 2008''

Revision as of 15:32, 21 February 2008

File:1psk.gif


1psk, resolution 2.8Å

Drag the structure with the mouse to rotate

THE CRYSTAL STRUCTURE OF AN FAB FRAGMENT THAT BINDS TO THE MELANOMA-ASSOCIATED GD2 GANGLIOSIDE

OverviewOverview

The GD2 ganglioside is a cell-surface component that appears on the surface of metastatic melanoma cells and is a marker for the progression of the disease. The ME36.1 monoclonal antibody binds to the GD2 ganglioside and has shown potential as a therapeutic antibody. ME36.1 is a possible alternative therapy to radiation, which is often ineffective in late-stage melanoma. The crystal structure of the Fab fragment of ME36.1 has been determined using molecular replacement and refined to an R factor of 20.4% at 2.8 A resolution. The model has good geometry with root-mean-square deviations of 0.008 A from ideal bond lengths and 1.7 degrees from ideal bond angles. The crystal structure of the ME36.1 Fab shows that its complementarity determining region forms a groove-shaped binding site rather than the pocket-type observed in other sugar binding Fabs. Molecular modeling has placed a four-residue sugar, representative of GD2, in the antigen binding site. The GD2 sugar moiety is stabilized by a network of hydrogen bonds that define the specificity of ME36.1 toward its antigen.

About this StructureAbout this Structure

1PSK is a Protein complex structure of sequences from Mus musculus. Full crystallographic information is available from OCA.

ReferenceReference

The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside., Pichla SL, Murali R, Burnett RM, J Struct Biol. 1997 Jun;119(1):6-16. PMID:9216084

Page seeded by OCA on Thu Feb 21 14:32:06 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA